rethinkTHC Search
Menu
Study breakdown

CBD Outperformed a Common Antipsychotic in Treating Autism-Like Behaviors in Zebrafish

Animal StudyPreliminary evidence
The takeaway

In a zebrafish model of autism, CBD reversed hyperactivity and aggression more effectively than risperidone, while also addressing underlying neurobiological changes.

Researchers studying cannabinoids in neurodevelopmental conditions; families following CBD research for autism

CBD normalized both glial markers and excitatory/inhibitory balance where risperidone did not

What the researchers found

CBD treatment reversed VPA-induced hyperlocomotion and aggression in zebrafish, reduced lipid peroxidation, restored anandamide levels, and normalized markers of glial function. Risperidone showed limited behavioral improvement and did not affect these neurobiological markers.

Why it matters

Risperidone is one of only two FDA-approved medications for autism-related irritability, but it comes with significant side effects. This study suggests CBD may address not just behavioral symptoms but some of the underlying neurobiology.

The numbers in context

CBD at 0.06 microM reversed both hyperlocomotion and aggression. CBD reduced lipid peroxidation and restored anandamide levels. CBD normalized both GFAP and calcium/calmodulin expression.

How the study worked

Zebrafish embryos were exposed to sodium valproate (VPA) to induce autism-like features. At 3-4 days post-fertilization, embryos were treated with 0.06 microM CBD or 1 microM risperidone.

What this study cannot tell us

Zebrafish model cannot replicate full complexity of human autism. VPA-induced autism model represents only one possible pathway to ASD. Results cannot be directly translated to human dosing.

How to read the evidence

Animal study in zebrafish; preclinical evidence that requires validation in mammalian models and human trials.

When this study was published

2025 study with current preclinical methods

The bigger picture

The endocannabinoid system plays an established role in neurodevelopment. This zebrafish study adds to preclinical evidence suggesting cannabinoids may have therapeutic potential in neurodevelopmental conditions.

Questions still open

  • Would these results hold in mammalian autism models? What dose of CBD in humans would correspond to the concentrations used here?

Common questions

Does this mean CBD can treat autism in humans?
Not yet. This is a zebrafish study, which is very early-stage research. Extensive mammalian studies and human clinical trials would be needed.
Why did CBD work better than risperidone in this model?
CBD appeared to address multiple biological pathways: reducing oxidative stress, restoring endocannabinoid levels, and normalizing glial and signaling proteins. Risperidone primarily works on dopamine and serotonin receptors.

Read the original research

Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate.

Autism research : official journal of the International Society for Autism Research, 18(12), 2368-2381

Citation

Costa, Karla C M; Brigante, Tamires A V; Lirio, Pedro H C; Fernandes, Gabriel G; Scarante, Franciele F; Scomparin, Davi S; Ferreira, Rafael R; Vicente, Maria A; Abe, Flavia R; Guimarães, Francisco S; Hallak, Jaime E C; Crippa, Jose A; de Oliveira, Danielle P; Campos, Alline C. (2025). Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate.. Autism research : official journal of the International Society for Autism Research, 18(12), 2368-2381. https://doi.org/10.1002/aur.70151

Explore the wider topic